Literature DB >> 1828424

A recombinant extracellular domain of the human interleukin 4 receptor inhibits the biological effects of interleukin 4 on T and B lymphocytes.

P Garrone1, O Djossou, J P Galizzi, J Banchereau.   

Abstract

Human interleukin 4 (IL4) acts on various hematopoietic cell types through interaction with a specific cell surface receptor (IL4R), whose cDNA has been cloned. We have produced a cDNA encoding a soluble form of the extracellular domain of the human IL 4R (sIL4R) and describe here the capacity of sIL4R to antagonize the in vitro activities of IL4 on normal B and T lymphocytes. sIL4R inhibited IL4-induced proliferation of both phytohemagglutinin-preactivated peripheral blood mononuclear cells (PBMC) and anti-IgM co-stimulated tonsil B cells with similar efficiency. This inhibitory activity was specific since sIL4R did not affect IL2-dependent proliferation of these cells. sIL4R also blocked IL4-dependent induction of the low-affinity receptor for IgE on B cells and inhibited IgE production by IL4-activated PBMC. Thus, in contrast to the IL6R extracellular domain which stimulates IL6 biological activity, the IL4R extracellular domain is a powerful antagonist of its specific ligand.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1828424     DOI: 10.1002/eji.1830210606

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  10 in total

Review 1.  Cytokines in asthma.

Authors:  K F Chung; P J Barnes
Journal:  Thorax       Date:  1999-09       Impact factor: 9.139

Review 2.  Regulation of IgE Responses by γδ T Cells.

Authors:  Yafei Huang; Zhifang Yang; Jessica McGowan; Hua Huang; Rebecca L O'Brien; Willi K Born
Journal:  Curr Allergy Asthma Rep       Date:  2015-04       Impact factor: 4.806

3.  Effects of meditation compared to music listening on biomarkers in breast cancer survivors with cognitive complaints: secondary outcomes of a pilot randomized control trial.

Authors:  Ashley M Henneghan; Brandon G Fico; Michelle L Wright; Shelli R Kesler; Michelle L Harrison
Journal:  Explore (NY)       Date:  2021-11-10       Impact factor: 2.358

4.  Modulation of cell-bound and soluble CD23, spontaneous and ongoing IgE synthesis of human peripheral blood mononuclear cells by soluble IL-4 receptors and the partial antagonistic IL-4 mutant protein IL-4 (Y124D).

Authors:  B König; A Fischer; W König
Journal:  Immunology       Date:  1995-08       Impact factor: 7.397

5.  Recombinant soluble interleukin-4 (IL-4) receptor acts as an antagonist of IL-4 in murine cutaneous Leishmaniasis.

Authors:  A Gessner; K Schröppel; A Will; K H Enssle; L Lauffer; M Röllinghoff
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

6.  Engineering of anti-human interleukin-4 receptor alpha antibodies with potent antagonistic activity.

Authors:  Jung-Eun Kim; Keunok Jung; Jeong-Ah Kim; Seung-Hyun Kim; Hae-Sim Park; Yong-Sung Kim
Journal:  Sci Rep       Date:  2019-05-23       Impact factor: 4.379

7.  Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid replacement.

Authors:  N Kruse; H P Tony; W Sebald
Journal:  EMBO J       Date:  1992-09       Impact factor: 11.598

8.  Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction.

Authors:  S M Zurawski; F Vega; B Huyghe; G Zurawski
Journal:  EMBO J       Date:  1993-07       Impact factor: 11.598

9.  Two distinct functional sites of human interleukin 4 are identified by variants impaired in either receptor binding or receptor activation.

Authors:  N Kruse; B J Shen; S Arnold; H P Tony; T Müller; W Sebald
Journal:  EMBO J       Date:  1993-12-15       Impact factor: 11.598

10.  Interleukin-4 (IL-4) enhances and soluble interleukin-4 receptor (sIL-4R) inhibits histamine release from peripheral blood basophils and mast cells in vitro and in vivo.

Authors:  B Niggemann; T Zuberbier; U Herz; K Enssle; U Wahn; H Renz
Journal:  Mediators Inflamm       Date:  1997       Impact factor: 4.711

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.